Showing 1 - 3 results of 3 for search 'E. Vandendries', query time: 0.02s Refine Results
  1. 1
    P579: A PHASE 4 STUDY OF FRACTIONATED GEMTUZUMAB OZOGAMICIN ON QT INTERVAL AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA

    P579: A PHASE 4 STUDY OF FRACTIONATED GEMTUZUMAB OZOGAMICIN ON QT INTERVAL AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA by P. Montesinos, V. Kota, J. Brandwein, P. Bousset, R. J. Benner, E. Vandendries, M. F. McMullin

    Published 2022-06-01
    Get full text
    Article
  2. 2
    PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

    PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by R. Fonseca, J. Kuroda, T. Ishida, R. Popat, J. S. Huang, A. Yver, E. Vandendries, M. Elmeliegy, W. D. Ma, D. W. Sborov

    Published 2022-06-01
    Get full text
    Article
  3. 3
    OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION

    OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION by M De-Lima, P Kebriaei, F Lanza, C Cho, G Popradi, M Kaur, M Zhang, F Zhang, E Vandendries, K Asomaning, S Dorman, M Stelljes, DI Marks, A Cury, W Saber

    Published 2023-10-01
    Get full text
    Article

Search Tools: